Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Mar;43(3):460-4.
doi: 10.1128/AAC.43.3.460.

In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems

Affiliations

In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems

W J Weiss et al. Antimicrob Agents Chemother. 1999 Mar.

Abstract

A series of novel aminomethyl tetrahydrofuranyl (THF)-1 beta-methylcarbapenems which have excellent broad-spectrum antibacterial activities exhibit modest efficacies against acute lethal infections (3.8 mg/kg of body weight against Escherichia coli and 0.9 mg/kg against Staphylococcus aureus) in mice when they are administered orally. In an effort to improve the efficacies of orally administered drugs through enhanced absorption by making use of a peptide-mediated transport system, several different amino acids were added at the aminomethyl THF side chains of the carbapenem molecules. The resulting peptidic prodrugs with L-amino acids demonstrated improved efficacy after oral administration, while the D forms were less active than the parent molecules. After oral administration increased (3 to 10 times) efficacy was exhibited with the alanine-, valine-, isoleucine-, and phenylalanine-substituted prodrugs against acute lethal infections in mice. Median effective doses (ED50s) of < 1 mg/kg against infections caused by S. aureus, E. coli, Enterobacter cloacae, or penicillin-susceptible Streptococcus pneumoniae were obtained after the administration of single oral doses. Several of the peptidic prodrugs were efficacious against Morganella morganii, Serratia marcescens, penicillin-resistant S. pneumoniae, extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, and E. coli infections, with ED50s of 1 to 14 mg/kg by oral administration compared with ED50s of 14 to > 32 mg/kg for the parent molecules. In general, the parent molecules demonstrated greater efficacy than the prodrugs against these same infections when the drugs were administered by the subcutaneous route. The parent molecule was detectable in the sera of mice after oral administration of the peptidic prodrugs.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Structures of THF carbapenems and peptidic prodrugs.
FIG. 2
FIG. 2
Levels of the parent THF carbapenem (CL 191,121) in serum determined by HPLC after oral administration of peptidic prodrugs to mice at 20 mg/kg. No drug was detected in serum after administration of the parent compound. ●, 121-Ile; □, 121-Val; ▴, 121-Ala.

Similar articles

Cited by

References

    1. Agouridas C, Bonnefoy A, Chantot J. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. In vivo antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F171; p. 143.
    1. Finney D. Probit analysis. 3rd ed. London, United Kingdom: Cambridge University Press; 1971.
    1. Fish D, Singletary T. Meropenem, a new carbapenem antibiotic. Pharmacotherapy. 1997;17:644–699. - PubMed
    1. Ford C, Hamel J, Wilson D, Moerman J, Stapert D, Yancey R, Hutchinson D, Barbachyn M, Brickner S. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother. 1996;40:1508–1513. - PMC - PubMed
    1. Fukuoka T, Ohya S, Utsui Y, Domon H, Takenouchi T, Koga T, Masuda N, Kawada H, Kakuta M, Kubota M, Ishii C, Sakagawa E, Harasaki T, Hirasawa A, Abe T, Yasuda H, Iwata M, Kuwahara S. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother. 1997;41:2652–2663. - PMC - PubMed

MeSH terms

LinkOut - more resources